

World's 1st Integrative Oncology Platform, ZenOnco.lo, Recognized at ESMO for Al-Based Free Cancer Treatment Guidance

ZenOnco.io's has been recognized at ESMO Annual Congress 2020 for its innovative solution to help millions of cancer patients with free cancer treatment report

MUMBAI, MAHARASHTRA, INDIA,
October 1, 2020 /EINPresswire.com/ -ZenOnco.io, the World's First
Integrative Oncology healthtech
platform, has received global
recognition at the European Society for
Medical Oncology (ESMO) Annual
Virtual Congress on September 21,
2020 for introducing the World's First



Artificial Intelligence-based tool to generate directional cancer treatment reports free of cost: ZIOPAR (ZenOnco.io Integrative Oncology Preliminary Assessment Report). This tool is accessible for free at https://zenonco.io/ziopar/. This is soon after ZenOnco.io launched India's first online cancer community – CANNECT dedicated to connecting cancer patients, survivors, caregivers and other healthcare professionals to share their experiences and knowledge to inspire each other. Cancer warriors can join CANNECT for free at https://zenonco.io/community/. Both these accomplishments have been in collaboration with its sister concern Love Heals Cancer (section 80G registered NGO). ZenOnco.io and Love Heals Cancer guide cancer patients free of cost in their treatment journey right from the beginning: This includes choosing the right oncologist / hospital, multi-disciplinary tumor board, getting diagnostic tests, managing side effects of treatment, chemo drugs at affordable price, onco-nutrition consultation, emotional wellness, home care, and connecting with other cancer warriors. ZenOnco.io provides 360-degree care to cancer patients through its in-house team of dedicated doctors available 24/7 to guide cancer patients in their treatment journey.

The ratio of oncologists to cancer patients is poor at 1:2000 in India, which results in a low quality of care for many cancer patients. 85% cancer patients prefer to know the possible treatment options. ZIOPAR provides Artificial Intelligence-based directional cancer treatment

reports free of cost to patients to guide them on possible treatment options, covering both medical as well as complementary treatment approaches. Cancer patients are required to provide six basic inputs that determine the output of the report (detailed up to 20-25 pages), with information on medical treatment options, diagnostic tests required, and complementary treatment approaches (including guidelines on nutrition, fitness, stress-management, and symptom management). ZIOPAR is based on standard protocols, guidelines and research by esteemed organizations in oncology, such as ESMO, Society of Integrative Oncology (SIO), National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), and others.

ZIOPAR has already benefitted 21,000+ cancer patients and caregivers across 16 countries by providing detailed directional cancer treatment reports. ZIOPAR is free to use to empower and educate millions of cancer patients in knowing their possible treatment options, asking the right questions to their doctors, and being confident in their treatment.

CANNECT is another free platform introduced by ZenOnco.io to make quality Integrative Oncology cancer care accessible to all. It connects cancer patients, survivors, caregivers and other healthcare professionals to share their experiences and knowledge to inspire each other.

Kishan Shah, Co-founder of ZenOnco.io and Love Heals Cancer, says "Being recognised globally at the ESMO Annual Virtual Congress 2020 is a testimony to our dedication to making quality Integrative Oncology cancer care accessible to all. ZIOPAR is the result of countless months of efforts puts in by oncologists, scientists, technology team and feedback from patients. It empowers cancer patients to ask the right questions to ensure that they are on the right treatment path. We have already helped 21,000+ cancer patients through ZIOPAR, but there is still a huge scope to help millions of more cancer patients. We are also very proud to launch India's first cancer community – CANNECT to bring together thousands of cancer warriors."

Dimple Parmar, Co-founder of ZenOnco.io and Love Heals Cancer, adds "ZIOPAR is an advanced tool based on Artificial Intelligence and protocols issued by international bodies. The purpose of the tool is to educate and empower cancer patients to know their indicative treatment plan on both medical as well as complementary treatment fronts. Along with guidance on treatment, we have also been receiving requests from thousands of cancer patients that they want to connect with other cancer warriors who have either gone through a similar cancer journey or are going through it. CANNECT brings together all cancer warriors so that they can connect with, learn from and inspire each other. Because we heal together in a community."

Link to ZIOPAR: https://zenonco.io/ZIOPAR/

Link to CANNECT: https://zenonco.io/community/

About ZenOnco.io and Love Heals Cancer

ZenOnco.io is the World's First Integrative Oncology healthtech platform; Love Heals Cancer is an Integrative Oncology-focused NGO (Non-Governmental Organization) registered under Section

80G of the Income-tax Act, 1961. Their common vision is to make quality Integrative Oncology cancer care accessible to all. Aim is to improve quality of life and extend life for cancer patients through Integrative Oncology treatment, which includes medical treatment as well as complementary treatment. ZenOnco.io has partnered with 150+ hospitals, 1,500+ oncologists, and 200+ diagnostic labs across India to provide medical treatment. ZenOnco.io also has a team of onco-nutritionists, onco-psychologists and physiotherapists to help cancer patients with side effect and symptom management to improve their quality of life. Together, both organizations have counseled 3,000+ cancer patients, organized 100+ events, and touched 15,000+ lives. ZenOnco.io and Love Heals Cancer are pioneers in changing cancer care through their technological innovations.

Nishant Singh
ZenOnco.io
+91 97699 91526
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/527442039

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.